In this retrospective observational analysis, we used pretreatment serum soluble receptor and cytokine/chemokine levels to identify reliable biomarkers to predict the week 16 DAS28-CRP score and remission/non-remission in RA patients who were administered tocilizumab or eternacept. Here, CRP is linked to rheumatoid arthritis.